The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, ...

Nektar Therapeutics (NASDAQ:NKTR) stock rose 7% Thursday following the announcement of encouraging outcomes from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for patients with moderate-to-severe ...

Adults with atopic dermatitis, whether diagnosed during childhood or adulthood, experienced higher rates of suicidal thoughts ...

A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals ...

US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE ...

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock jumped 7% Thursday after the company announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe ...

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

Findley Dermatology, founded by board-certified dermatologist and Mohs Surgeon Dr. Alyssa Findley, is dedicated to patient-centered care with a personal touch—treating every patient like family.